Senhwa Biosciences, Inc., a Taiwan and San Diego, CA-based developer of anticancer agents, raised an additional USD$17m Series B financing.
Backers included H&Q Asia Pacific, Morningside and China Investment & Development Co., Ltd.
The company intends to use the funds to continue the development of its anticancer agents CX-5461 and CX-4945 and take them through clinical proof-of-concept studies.
Led by Dr. Tai-Sen Soong, President of Senhwa Biosciences develops:
– an anticancer compound for treating hematological malignancies, CX-5461, a p53 activating, Pol I inhibitor, currently in a Phase I clinical trial at the Peter MacCallum Cancer Centre in Melbourne, Australia.
– a CK2 inhibitor, CX-4945, which is being developed for combination treatment in solid tumors with the commonly used chemotherapy agents gemcitabine and cisplatin.